ArticlePloS one2018
Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07512401 (Safety of Reduced Methotrexate Lab Monitoring), which is not on this map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Reduced Methotrexate Lab Monitoring: a Population-based, Target Trial Emulation Study
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- Systematic review: development of a consensus code set to identify cirrhosis in electronic health records.Alimentary pharmacology & therapeutics · 2022Pooled it
- Models for acute on chronic liver failure development and mortality in a veterans affairs cohort.Hepatology international · 2020Trial
- Elective colorectal surgery in those with cirrhosis: a population-based study assessing practice patterns and patient outcomes.Journal of the Canadian Association of Gastroenterology · 2026Article
- The rate of and risk factors for falls among patients with cirrhosis: A multicenter study.Hepatology communications · 2026Article
- The association between cirrhosis and outcomes among patients with lung cancer in Ontario between 2007 and 2017: A population-based study.Canadian liver journal · 2026Article
- Cardiometabolic comorbidity and health outcomes of persons with metabolic dysfunction-associated steatotic liver disease (MASLD) in Ontario, Canada.Canadian liver journal · 2026Article
- Association between early methadone dose titration and treatment discontinuation and opioid toxicity: A retrospective cohort study.PLoS medicine · 2026Article
- Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: A population-based case-control study.PLoS medicine · 2026Article
- A Response to: Letter to the Editor Regarding "Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States".Infectious diseases and therapy · 2026Article
- Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study.Journal of comparative effectiveness research · 2026Observational
- Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort.Hepatology (Baltimore, Md.) · 2026Article
- Multiple Maternal Chronic Conditions and Risk of Severe Neonatal Morbidity and Mortality.JAMA network open · 2026Article
- Multiple Chronic Conditions Before Pregnancy and Risk of Adverse Maternal Health Outcomes: Population-Based Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- Short- and Long-Term Healthcare Costs Attributable to Hepatitis B Among Newcomers to Ontario, Canada: A Matched Cohort Study.Canadian journal of gastroenterology & hepatology · 2026Article
- Impact of tenofovirJHEP reports : innovation in hepatology · 2025Article
- The Impact of COVID-19 and Related Public Health Measures on Hepatitis C Testing in Ontario, Canada.Viruses · 2025Article
- Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.Hepatology (Baltimore, Md.) · 2025Article
- High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- The Impact of New Direct-Acting Antiviral Therapy on the Prevalence and Undiagnosed Proportion of Chronic Hepatitis C Infection in Alberta: A Model-Based Analysis.Canadian liver journal · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate screening and treatment strategies, large-scale real-world data on liver disease-related outcomes are needed. We sought to validate health administrative data for identification of cirrhosis, decompensated cirrhosis and hepatocellular carcinoma among patients with known liver disease.
methodsPrimary patient data were abstracted from patients of the Toronto Center for Liver Disease with viral hepatitis (2006-2014), and all patients with liver disease from the Kingston Health Sciences Centre Hepatology Clinic (2013). We linked clinical information to health administrative data and tested a range of coding algorithms against the clinical reference standard.
resultsA total of 6,714 patients had primary chart data abstracted. A single physician visit code for cirrhosis was sensitive (98-99%), and a single hospital diagnostic code for cirrhosis was specific (91-96%). The most sensitive algorithm for decompensated cirrhosis was one cirrhosis code with any of: a hospital diagnostic code, death code, or procedure code for decompensation (range 88-99% across groups). The most specific was one cirrhosis code and one hospital diagnostic code (range 89-98% across groups). Two physician visit codes or a single hospital diagnostic code, death code, or procedure code combined with a code for cirrhosis were sensitive and specific for hepatocellular carcinoma (sensitivity 94-96%, specificity 93-98%).
conclusionThese sensitive and specific algorithms can be used to define patient cohorts or detect clinical outcomes using health administrative data. Our results will facilitate research into the adequacy of screening and treatment for patients with chronic viral hepatitis or other liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.